Pharming Group N.V.

If approved, Joenja will be the first approved treatment in the U. S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosingSeparate sNDA for lower weight pediatric patients planned for second half 2026 Leiden, the Netherlands, June 4, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.

globenewswire.com - 2026-06-04 01:00:00

Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

globenewswire.com - 2026-06-04 01:00:00

Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.

globenewswire.com - 2026-05-28 10:40:00

Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue declined as inventory dynamics played out CEO Fabrice Chouraqui said quarterly revenue fell primarily due to RUCONEST, a decline he said was “largely expected due to inventory drawdown at specialty pharmacy,” which the company previously discussed on its fourth-quarter 2025 call.

marketbeat.com - 2026-05-08 16:03:05

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 12:41:18

Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA.

globenewswire.com - 2026-05-07 01:05:00

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026.

globenewswire.com - 2026-05-07 01:00:00

Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR - Get Free Report) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 12,882 shares, a decline of 15.5% from the March 15th total of 15,251 shares. Approximately 0.0% of the company's shares are sold short. Based

defenseworld.net - 2026-04-19 04:50:42

Earth Science Tech (OTCMKTS:ETST - Get Free Report) and Pharming Group (NASDAQ: PHAR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation. Profitability This table compares Earth Science

defenseworld.net - 2026-04-17 01:44:49

Pharming Group N.V. 2026 Annual General Meeting to be be held on Thursday May 28, 2026, at 14:00 CET. Meeting documents available on website Pharming.com.

globenewswire.com - 2026-04-16 02:00:00